DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer Meeting Abstract
| Authors: | Niazi, T.; McBride, S. M.; Williams, S.; Davis, I. D.; Stockler, M. R.; Martin, A. J.; Chung, H. T.; Roncolato, F.; Ebacher, A.; Khoo, E.; Martin, J.; Lim, T. S.; Hughes, S.; Pryor, D.; Catto, J. W. F.; Kelly, P.; Gholam Rezaei, L.; Morgan, S. C.; Rendon, R. A.; Sweeney, C.; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) |
| Abstract Title: | DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer |
| Meeting Title: | 2023 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2023 Feb 16-18 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-20 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.6_suppl.TPS396 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS396 -- Source: Cinahl |
